Measuring melasma patients' quality of life using willingness to pay and time trade-off methods in thai population

BMC Dermatology

Volumn 11, Issue , 2011, Pages

  Leeyaphan, Charussri ^a   Wanitphakdeedecha, Rungsima ^a   Manuskiatti, Woraphong ^a   Kulthanan, Kanokvalai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; HYDROQUINONE; RETINOIC ACID; STEROID; SUNSCREEN;

ADULT; ARTICLE; CHLOASMA; CROSS-SECTIONAL STUDY; EDUCATION; FEMALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MARRIAGE; OCCUPATION; QUALITY OF LIFE; QUESTIONNAIRE; TIME TRADE OFF; TREATMENT DURATION; WILLINGNESS TO PAY; AGED; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH STATUS; LONGEVITY; MELANOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGICAL ASPECT; STATISTICS; THAILAND;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; FINANCING, PERSONAL; HEALTH STATUS; HUMANS; INCOME; LONGEVITY; MALE; MELANOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRES; THAILAND;

EID: 83655191663     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-11-16     Document Type: Article

References (32)

1. El-Essawi D, Musial JL, Hammad A, Lim HW. A survey of skin disease and skin-related issues in Arab Americans. J Am Acad Dermatol 2007, 56:933-8.
2. Duarte I, Campos Lage AC. Frequency of dermatoses associated with cosmetics. Contact Derm 2007, 56:211-3.
3. Hide L, Barbara B, Sofie DS, Evelien V, Katie O, Nanja G. Hypomelanoses and hypermelanoses. Fitzpatrick's Dermatology in General Medicine 2008, 622-40. New York: McGraw Hill, Wolff K, Goldsmith LA, Katz S, Gilchrest BA, Paller AS, Leffell DJ, 7.
4. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981, 4:698-710.
5. Kulthanan K. Pigmentary disorder. Dermatology 2010 2005, 100-19. Bangkok: Holistic Publishing, Kullavanijaya P, Pisalbutra P.
6. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997, 136:305-14.
7. Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient?. Br J Cancer 1988, 57:109-12.
8. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999, 141:1067-75.
9. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida AR, Rego VR, Mendes AM, Filho JW, Jungueira H. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol 2006, 156(Suppl 1):13-20.
10. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006, 55:1048-65.
11. McCombs K, Chen SC. Patient preference quality of life measures in dermatology. Dermatol Ther 2007, 20:102-9.
12. Kulthanan K, Jiamton S, Wanitphakdeedecha R, Chantharujikaphong S. The validity and reliability of the Dermatology Life Quality Index (DLQI) in Thais. Thai J Dermatol 2004, 20:113-23.
13. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003, 149:572-7.
14. Froberg DG, Kane RL. Methodology for measuring health-state preferences--I: Measurement strategies. J Clinical Epidemiol 1989, 42:345-54.
15. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients?. Br J Dermatol 2003, 148:1153-60.
16. Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Invest Dermatol Symp Proc 2004, 9:160-8.
17. Zug KA, Littenberg B, Baughman RD, Kneeland T, Nease RF, Sumner W, O'Connor GT, Jones R, Morrison E, Cimis R. Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 1995, 131:561-8.
18. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995, 132:236-44.
19. Chen S, Shaheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs. Goeckerman therapy for psoriasis. A pilot study. Arch Dermatol 1998, 134:1602-8.
20. Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. J Eur Acad Dermatol Venereol 2000, 14:153-8.
21. Schiffner R, Brunnberg S, Hohenleutner U, Stolz W, Landthaler M. Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. Br J Dermatol 2002, 146:440-7.
22. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006, 154:1137-46.
23. Motley RJ, Finlay AY. How much disability is caused by acne?. Clin Exp Dermatol 1989, 14:194-8.
24. Parks L, Balkrishnan R, Hamel-Gariepy L, Feldman SR. The importance of skin disease as assessed by "willingness-to-pay". J Cutan Med Surg 2003, 7:369-71.
25. Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, Menter A, Baumann L, Weider JJ, Jarratt MM, Pariser D, Martin D, Weiss J, Shavin J, Ramirez N. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003, 72:67-72.
26. Sivayathorn A. Melasma in Orientals. Clin Drug Invest 1995, 10:34-40.
27. Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in southern Brazil. J Eur Acad Dermatol Venereol 2008, 22(6):655-62.
28. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006, 4:71.
29. Schmitt J, Meurer M, Klon M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2008, 158:351-9.
30. Dogramaci AC, Havlucu DY, Inandi T, Balkrishnan R. Validation of a melasma quality of life questionnaire for the Turkish language: The MelasQoL-TR study. J Dermatolog Treat 2009, 20(2):95-9.
31. Chie WC, Huang CS, Chen JH, Chang KJ. Utility assessment for different clinical phases of breast cancer in Taiwan. J Formos Med Assoc 2000, 99(9):677-83.
32. Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002, 12(2):160-78.